PDE 10a Inhibitors for the Treatment of Type II Diabetes
申请人:Janssen Pharmaceutica, NV
公开号:US20140364413A1
公开(公告)日:2014-12-11
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows:
wherein R
1
, R
2
, L, and Q are defined herein.
NON-ENZYMATIC SYNTHESIS OF O-ACETYL-ADP-RIBOSE AND ANALOGUES THEREOF
申请人:Koppetsch Karsten
公开号:US20150218202A1
公开(公告)日:2015-08-06
Provided herein is a simple, one-step, non-enzymatic synthesis of O-Acetyl-ADP-ribose (OAADPR) from NAD and sodium acetate in acetic acid. The extension of this reaction to other carboxylic acids, demonstrates that the reaction between NAD, and NAD analogs produces mixtures of the corresponding 2′- and 3′-carboxylic esters. Included are O-carboxyl-ADP-ribose compounds and corresponding methods of synthesis (e.g., O-propionyl-ADP-ribose, O-succinyl-ADP-ribose, O-malonyl-ADP-ribose), as well as non-adenosine nucleoside compounds.
SYNTHESIS OF SOME PEPTIDES OF ε-N-ACETYL-<scp>L</scp>-LYSINE
作者:Leo Benoiton
DOI:10.1139/v63-246
日期:1963.7.1
ε-N-Acetyl-L-lysinamide, α-N-glycyl-ε-N-acetyl-L-lysine, ε-N-acetyl-L-lysylglycine, α-N-glycyl-ε-N-acetyl-L-lysylglycine, and ε-N-acetylglycyl-L-lysine have been synthesized for testing as substrates for the enzyme ε-lysine acylase.